NCT06124482 Performance and Safety Evaluation of the FHK®-CK Knee Prosthesis
| NCT ID | NCT06124482 |
| Status | Recruiting |
| Phase | — |
| Sponsor | FH ORTHO |
| Condition | Total Knee Arthroplasty |
| Study Type | INTERVENTIONAL |
| Enrollment | 92 participants |
| Start Date | 2024-02-01 |
| Primary Completion | 2028-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 92 participants in total. It began in 2024-02-01 with a primary completion date of 2028-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The life expectancy worldwide is increasing and leading to an increase of knee arthroplasty. Also, as millions of people around the world are currently living with a Total Knee Arthroplasty (TKA), the need for revision surgery represents a large public health burden. In this context, FH ORTHO company develops FHK®-CK (prosthesis + ancillary equipment) which is a knee prosthesis for complex first intention and revision knee arthroplasty. This new medical device complements the FHK® standard first-line range (CE marked). The FHK®-CK ancillary equipment were designed by expert knee surgeons and is simple, reliable and reproducible. It allows for maximum versatility while remaining compact. By completing the FHK® range of first intention prostheses, the FHK®-CK allows the surgeon to be on the same level as the competitors by having a first intention and semi-constrained prosthesis. This prosthetic arsenal allows the surgeon to opt for the best solution for his patient so that he can regain mobility and a satisfactory quality of life. Also, in case of failure of the FHK® first-line prosthesis, it will provide the surgeon and the patient with a simple alternative to prosthesis replacement. As it has been developed in line with the first intention, inter-compatibility between the two systems is possible, which simplifies the surgical procedure and reduces the risks for the patient.
Eligibility Criteria
Inclusion Criteria: * Patient requiring knee arthroplasty for primary or secondary gonarthrosis: \* For primary intention arthroplasty: Patient with either * major axial deviation, * major peripheral failure or * bone defect; \* For prosthesis revision surgery: Patient who have had a failed 1st implantation, with or without bone defects. * Patient able to understand and answer the questionnaires provided by the protocol; * Subject affiliated to a health insurance system or is a beneficiary; * Signed informed consent form (ICF) for participation to the research. Exclusion Criteria: * Patient with an ongoing acute infection, outside knee to be operated; * Patient with a mental or neuromuscular disorder that would create an unacceptable risk of prosthetic instability, prosthetic fixation failure or post-operative complications; * Patient with a known allergy to any of the components of the FHK®-CK implants (Nickel, Cobalt, Chromium); * Patient with a dependency (drug, alcohol,…) that could affect his/ her ability to comply with the protocol, at the investigator's discretion; * Patient requiring knee reconstruction; * Patient with any medically significant findings or significant history that may impact the safety, interpretation of results, and/ or participation of the subject in the clinical trial, as determined by the investigator; * Patient with an existing knee or hip prosthesis (outside knee to be operated) that may impact the evaluation of the FHK®-CK prosthesis; * Patient concurrently participating in another clinical trial or who has recently participated in another clinical trial for which the exclusion period has not been completed. * Vulnerable subjects : * Pregnant, parturient, or breastfeeding women, * Subject deprived of liberty, hospitalized without consent or admitted to a health or social establishment for purposes other than that of research, * Minor, * Adult under protective supervision (tutorship, curatorship), * Subject not able to understand the subject information leaflet (e.g. for linguistic or psychiatric reasons) and/or to give informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06124482 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Total Knee Arthroplasty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06124482 currently recruiting?
Yes, NCT06124482 is actively recruiting participants. Contact the research team at c.carre@fhortho.com for enrollment information.
Where is the NCT06124482 trial being conducted?
This trial is being conducted at Beaumont, France, Brest, France, Clichy, France, Garches, France and 3 additional locations.
Who is sponsoring the NCT06124482 clinical trial?
NCT06124482 is sponsored by FH ORTHO. The trial plans to enroll 92 participants.